Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 8/20 | 1.00 |
| ▸ | MTNR1B | P49286 | 8/20 | 1.00 |
| ▸ | NQO2 | P16083 | 6/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1724140 | 1.00 | MTNR1A (1.00) | MTNR1AMTNR1BNQO2CYP19A1CYP11B2 | |
| SCHEMBL1724137 | 1.00 | MTNR1A (1.00) | MTNR1AMTNR1BNQO2CYP19A1CYP11B2 | |
| SCHEMBL4688512 | 0.89 | MTNR1A (0.80) | MTNR1AMTNR1BNQO2CYP19A1CYP11B2 | |
| SCHEMBL4688514 | 0.89 | MTNR1A (0.80) | MTNR1AMTNR1BNQO2CYP19A1CYP11B2 | |
| SCHEMBL4688517 | 0.89 | MTNR1A (0.80) | MTNR1AMTNR1BNQO2CYP19A1CYP11B2 | |
| SCHEMBL4689419 | 0.88 | MTNR1A (0.78) | MTNR1AMTNR1BNQO2CYP19A1CYP11B2 | |
| SCHEMBL4689417 | 0.88 | MTNR1A (0.78) | MTNR1AMTNR1BNQO2CYP19A1CYP11B2 | |
| SCHEMBL4689415 | 0.88 | MTNR1A (0.78) | MTNR1AMTNR1BNQO2CYP19A1CYP11B2 | |
| SCHEMBL7951201 | 0.86 | MTNR1A (0.75) | MTNR1AMTNR1BNQO2CYP19A1CYP11B2 | |
| SCHEMBL7951204 | 0.86 | MTNR1A (0.75) | MTNR1AMTNR1BNQO2CYP19A1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2406242-B1 | PROCESS FOR THE PREPARATION OF RAMELTEON | IND CHIMICA SRL (IT) | 2013-06-05 | — | — | EP | disclosed |
| US-8242291-B2 | Process for the preparation of ramelteon | INDUSTRIALE CHIMICA S.R.L. (IT) | 2012-08-14 | — | — | US | disclosed |
| EP-2406242-A1 | PROCESS FOR THE PREPARATION OF RAMELTEON | Industriale Chimica S.R.L. (IT) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010103553-A1 | PROCESS FOR THE PREPARATION OF RAMELTEON | INDUSTRIALE CHIMICA S.R.L. (IT) | 2010-09-16 | — | — | WO | disclosed |
| US-20100234622-A1 | PROCESS FOR THE PREPARATION OF RAMELTEON | INDUSTRIALE CHIMICA S.R.L (IT) | 2010-09-16 | — | — | US | disclosed |
| EP-0885210-B2 | Tricylic compounds having binding affinity for melatonin receptors, their production and use | TAKEDA PHARMACEUTICAL (JP) | 2008-06-18 | — | — | EP | disclosed |
| EP-1550655-A1 | Bicyclic intermediates | Takeda Pharmaceutical Company Limited (JP) | 2005-07-06 | — | — | EP | disclosed |
| EP-0885210-B1 | Tricylic compounds having binding affinity for melatonin receptors, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-06-12 | — | — | EP | disclosed |
| EP-1199304-A1 | Bicyclic compounds and pharmaceutical composition containing tricyclic compound for treating or preventing sleep disorders | Takeda Chemical Industries, Ltd. (JP) | 2002-04-24 | — | — | EP | disclosed |
| US-6218429-B1 | TREATING MELATONIN RELATED DISORDERS (E.G. CIRCARDIAN RHYTHMS, SLEEP-AWAKE CYCLES, TIME ZONE CHANGES, SLEEP DISORDERS) | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-17 | — | — | US | disclosed |
| US-6034239-A | BINDIG TO MELATONIN RECEPTORS; SLEEP DISORDERS; GLANDULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-03-07 | — | — | US | disclosed |
| EP-0885210-A1 | Tricylic compounds having binding affinity for melatonin receptors, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997032871-A1 | TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234622-A1 | PROCESS FOR THE PREPARATION OF RAMELTEON | CYP2B6, CYP2A6, UGT1A6 | MTNR1A 998/4885MTNR1B 779/4885NQO2 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.